Tagged: epizyme
2 results
Michael Shih
Michael Shih is the Chief Executive Officer of NeoPhore Ltd, a London-based small molecule neoantigen immuno-oncology company developing first-in-class drugs that target the DNA mismatch repair (MMR) pathway to make cancers more visible to the immune system. An attorney by training with degrees in biology, he spent nearly two decades structuring biotech deals before sitting in the chief executive's chair, with senior business development and corporate development roles at Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics and Eisai. He took the helm at NeoPhore in December 2024, right after the company closed an oversubscribed Series B round backed by Bristol Myers Squibb.
Michael Boretti
Michael Boretti is the Chief Business Officer of Solu Therapeutics, a Boston biotech building a new class of cell-killing medicines on its CyTaC (Cytotoxicity Targeting Chimera) platform licensed from GSK. A bioengineer-turned-dealmaker with roughly two decades in biopharma, Boretti leads business development, strategic financing and alliance management. His earlier stops include CBO of Celsius Therapeutics, VP of Business Development at Epizyme, and VP of Corporate Development and Alliance Management at AVEO Oncology, where he helped shape partnerships with Astellas, Novartis and Janssen. He holds a B.S. in engineering science from the University of Virginia and a Ph.D. in bioengineering from the University of Pennsylvania.